The weeks leading into winter are often the ideal time to address sinus issues. By improving sinus function before cold and ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Sanofi & Regeneron’s Dupixent pivotal study meets all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis: Paris Monday, November 10, ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
Results from the pivotal LIBERTY-AFRS-AIMS phase 3 study evaluating the investigational use of Dupixent in adults and children aged 6 years and ...
ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...
Crystal Flush is a legitimate antifungal system backed by an FDA-approved active ingredient and science-based formulation—but like any effective fungus treatment, results take time and consistency.
The author has completed the ICMJE form and declares no conflicts of interest. A male patient in his late seventies presented with double vision and left abducens nerve palsy. Imaging revealed sinus ...
Europe’s Pharmacovigilance Risk Assessment Committee (PRAC) has issued a new safety warning about the management of renal dialysis in critically ill patients receiving the antifungal agent caspofungin ...
Introduction There are no clear guidelines for deciding between endoscopic sinus surgery and tooth extraction for the treatment of odontogenic sinusitis. Furthermore, tooth extraction does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback